| 66.81 2.58 (4.02%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 78.61  |
1-year : | 91.82 |
| Resists | First : | 67.3 |
Second : | 78.61 |
| Pivot price | 63.43 |
|||
| Supports | First : | 63.07 |
Second : | 60.45 |
| MAs | MA(5) : | 64.06 |
MA(20) : | 63.14 |
| MA(100) : | 76.05 |
MA(250) : | 70.92 |
|
| MACD | MACD : | -0.5 |
Signal : | -1.1 |
| %K %D | K(14,3) : | 71.5 |
D(3) : | 54.9 |
| RSI | RSI(14): 57.2 |
|||
| 52-week | High : | 94.86 | Low : | 53.79 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BRKR ] has closed It is unclear right now based on current values. 40.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 67.39 - 67.65 | 67.65 - 67.91 |
| Low: | 63.99 - 64.29 | 64.29 - 64.6 |
| Close: | 66.31 - 66.78 | 66.78 - 67.26 |
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Thu, 25 Jul 2024
Bruker (BRKR) Earnings Expected to Grow: What to Know Ahead of Q2 Release - Yahoo Finance
Wed, 24 Jul 2024
Vanguard Group Inc. Sells 36,337 Shares of Bruker Co. (NASDAQ:BRKR) - MarketBeat
Wed, 24 Jul 2024
Vanguard Group Inc. Sells 36,337 Shares of Bruker Co. (NASDAQ:BRKR) - Defense World
Tue, 23 Jul 2024
ProShare Advisors LLC Has $664,000 Stock Holdings in Bruker Co. (NASDAQ:BRKR) - Defense World
Mon, 22 Jul 2024
Is It Too Late To Consider Buying Bruker Corporation (NASDAQ:BRKR)? - Simply Wall St
Wed, 29 May 2024
Bruker Announces Pricing of Public Offering of Common Stock - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 151 (M) |
| Shares Float | 99 (M) |
| Held by Insiders | 31.8 (%) |
| Held by Institutions | 74.9 (%) |
| Shares Short | 3,530 (K) |
| Shares Short P.Month | 4,280 (K) |
| EPS | 2.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.73 |
| Profit Margin | 13.3 % |
| Operating Margin | 11 % |
| Return on Assets (ttm) | 6.6 % |
| Return on Equity (ttm) | 30.2 % |
| Qtrly Rev. Growth | 5.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 19.82 |
| EBITDA (p.s.) | 3.71 |
| Qtrly Earnings Growth | -32.8 % |
| Operating Cash Flow | 284 (M) |
| Levered Free Cash Flow | 272 (M) |
| PE Ratio | 24.47 |
| PEG Ratio | 1.9 |
| Price to Book value | 6.85 |
| Price to Sales | 3.37 |
| Price to Cash Flow | 35.55 |
| Dividend | 0.05 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|